# Baxter International **Source:** https://geo.sig.ai/brands/baxter-international **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** baxter.com **Last Updated:** 2026-04-14 ## Summary Deerfield IL hospital medical technology (NYSE: BAX) at $10.636B 2024 revenue; Vantive kidney care sold to Carlyle $3.8B (Jan 2025), new CEO Andrew Hider (Sep 2025) competing with ICU Medical for IV solutions and infusion systems. ## Company Overview Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system. Baxter's hospital products and medical technology model addresses the critical care and nutritional support requirements of acute care patients whose conditions require sterile pharmaceutical delivery systems: patients in ICUs, surgical recovery, and long-term care settings require IV fluid and medication delivery that cannot tolerate the contamination risk of compounding pharmacy preparations — and Baxter's factory-prepared IV bags, infusion pumps (SIGMA Spectrum), and parenteral nutrition formulations provide the sterility, dosing accuracy, and clinical workflow integration (BCMA barcode scanning compatibility) that hospital pharmacy and nursing protocols require. Baxter's Hillrom-derived digital health platforms (acquired via the 2022 Hillrom acquisition for $12.5B) include the Welch Allyn vital signs monitoring, Voalte clinical communication, and Centrella smart bed technologies that create the connected care infrastructure for hospital efficiency improvement. In 2025, Baxter competes in the IV solutions, infusion systems, hospital medical products, and clinical technology market with ICU Medical (NASDAQ: ICUI, IV solutions and infusion, $5.6B revenue after Smiths Medical acquisition), B. Braun (private, German medical, €8B revenue), and Becton Dickinson (NYSE: BDX, infusion and drug delivery, $20.2B revenue) for hospital system GPO contracts, IV solution supply agreements, and smart infusion pump technology placements. The Vantive divestiture ($3.8B to Carlyle, January 2025) ends Baxter's 90-year presence in kidney care — an exit that simplifies the company's portfolio to hospital-focused acute care and surgical products. The new CEO (Andrew Hider, September 2025) arrives with a mandate for operational improvement: Baxter's infusion system market share has faced competitive pressure from ICU Medical and BD following manufacturing disruptions. The 2025 strategy focuses on restoring IV solutions supply chain reliability, integrating the remaining digital health platforms, and improving operating margins under Hider's operational leadership. ## Frequently Asked Questions ### What does Baxter International do? Baxter International is a global medical technology company that develops, manufactures, and commercializes healthcare products and digital health solutions. The company specializes in sterile IV solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and hospital care products. Baxter serves hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and home healthcare settings worldwide with 38,000 employees and $10.636 billion in 2024 revenue. ### When was Baxter International founded? Baxter International was founded in 1931 in Los Angeles, California, by Dr. Donald Baxter and Dr. Ralph Falk as the Don Baxter Intravenous Products Corporation. The company became the first commercial manufacturer of prepared IV solutions in the United States, pioneering sterile intravenous therapy that revolutionized hospital care and patient treatment. ### Where is Baxter International headquartered? Baxter International is headquartered at One Baxter Parkway, Deerfield, Illinois 60015, United States. The main telephone number is (847) 948-2000. The Deerfield campus is a 160-acre site serving as Baxter's global headquarters, featuring administrative offices, research and development facilities, a fitness center, cafeteria, and outdoor wellness spaces for employees. ### Who are Baxter International's customers? Baxter's customers include hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients receiving home healthcare under physician supervision. The company serves healthcare providers and patients across the Americas, Europe, Middle East, Africa, and Asia-Pacific regions with critical medical products for acute care, nutritional support, renal therapy, surgical procedures, and hospital operations. ### What makes Baxter International different from competitors? Baxter differentiates itself through its pioneering legacy of healthcare innovation, being the first commercial manufacturer of prepared IV solutions (1931) and the first to introduce a commercially-built kidney dialysis system (1956). The company's integrated portfolio spans IV solutions, infusion systems, nutrition, surgical products, and digital health solutions, allowing comprehensive support for hospital operations. Baxter's culture of innovation, founded on partnership, trust, accountability, and agility, drives meaningful innovations that make a difference for millions of patients worldwide. ### Who are Baxter International's main competitors? Baxter's main competitors include Fresenius Medical Care (the world's leading provider of kidney dialysis with 345,000 patients in 4,100+ clinics globally), DaVita Inc. (operating 2,900+ dialysis clinics serving 225,000+ patients), and B. Braun Melsungen AG (major player in dialysis machines and medical supplies). These companies compete in dialysis products and services, IV solutions, infusion systems, and hospital care products across multiple therapeutic areas. ### What is Baxter International's revenue? Baxter International reported 2024 annual revenue of $10.636 billion from continuing operations, representing a 2.66% increase from 2023. The company's Medical Products and Therapies segment contributed $5.21 billion (49% of total revenue) over the trailing 12-month period. For Q4 2024, worldwide sales from continuing operations totaled approximately $2.75 billion, increasing 1% on a reported basis and 2% on a constant currency basis. ### How many employees does Baxter International have? Baxter International had 38,000 employees as of December 31, 2024. This represents a decrease from 60,000 employees in 2023, primarily due to corporate divestitures including the sale of the kidney care business (Vantive) to Carlyle Group for $3.8 billion and the biopharma solutions business for $4.25 billion. Employees are located across operations in the Americas, Europe, Middle East, Africa, and Asia-Pacific. ### Is Baxter International publicly traded? Yes, Baxter International is publicly traded on the New York Stock Exchange under the ticker symbol BAX (NYSE: BAX). As of mid-2025, Baxter has a market capitalization of approximately $15 billion. The company has faced recent challenges including operational issues and guidance reductions, with the stock trading near 20-year lows in early 2025 before new leadership was announced. ### What happened with Hurricane Helene and IV fluid shortage? In September 2024, Hurricane Helene caused significant flooding at Baxter's manufacturing facility in Marion, North Carolina, which produces approximately 60% of the intravenous (IV) fluids used in the United States. This created a national healthcare supply challenge. As of November 7, 2024, the facility resumed producing some IV fluids, with Baxter working to restore full production capacity and address the nationwide shortage. ### Is Baxter International hiring? Yes, Baxter International regularly hires across various departments including Research & Development, Engineering, Operations, IT, Finance, Human Resources, Legal, and other areas. The careers website is available at jobs.baxter.com where candidates can search for opportunities at the Deerfield headquarters and other global locations. Baxter offers market-competitive pay, comprehensive benefits, workplace flexibility, paid parental leave, and professional development opportunities. ### What are Baxter International's recent developments? Recent major developments include the appointment of Andrew Hider as president and CEO in July 2025 (effective September 2025), completion of the Vantive kidney care business sale to Carlyle for $3.4 billion in January 2025, and recovery from Hurricane Helene's impact on IV fluid production. The company is focused on operational excellence and expects 5-6% sales growth from continuing operations in 2025 with adjusted earnings of $2.45-$2.55 per diluted share. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*